Results 191 to 200 of about 137,192 (357)

Toxicity prediction and analysis of flavonoid apigenin as a histone deacetylase inhibitor: an in-silico approach. [PDF]

In Silico Pharmacol, 2023
Divya Rajaselvi N, Jida MD, Nair DB, Sujith S, Beegum N, Nisha AR.   +5 more
europepmc   +1 more source

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines

, 2022
Yukiko Hazama, Takayuki Tsujioka, Akira Kitanaka, Kaoru Tohyama, Koichiro Shimoya   +4 more
openalex   +2 more sources

Alterations in brain metabolites in rats with experimental periodontitis: A metabolomic approach

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis (PD) is a chronic inflammatory disease with systemic effects. Emerging evidence suggests a link between periodontal inflammation and neurological changes, but the biochemical mechanisms in key brain regions, such as the hippocampus and amygdala, remain unclear.
Ramona Ramalho de Souza Pereira, Caíque Olegário Diniz e Magalhães, Elizabeth Luciana Marinho Miguel, Larissa Vieira Toledo, Débora Ribeiro Orlando, Alan Rodrigues Teixeira Machado, Bruno Del Bianco Borges, Luciano José Pereira, Marco Fabrício Dias‐Peixoto, Eric Francelino Andrade   +9 more
wiley   +1 more source

Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases [PDF]

, 2011
Nadezhda V. Koshkina, Krithi Rao Bindal, Eugenie S. Kleinerman   +2 more
openalex   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor. [PDF]

Cancers (Basel), 2023
Ashry R, Mustafa AM, Hausmann K, Linnebacher M, Strand S, Sippl W, Wirth M, Krämer OH.   +7 more
europepmc   +1 more source

A Focus on the Preclinical Development and Clinical Status of the Histone Deacetylase Inhibitor, Romidepsin (Depsipeptide, Istodax^®)

, 2012
Simon J. Harrison, Mark Bishton, Susan E. Bates, Steven Grant, Richard Piekarz, Ricky W. Johnstone, Yun Dai, Becki Lee, Maria Elisa Melo Branco de Araújo, H. Miles Prince   +9 more
openalex   +2 more sources

Rosuvastatin Upregulates RCOR1 to Repress C10ORF10 Transcription and Alleviate Oxidative Stress and Plaque Formation in Atherosclerosis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Rosuvastatin (RVS) is an HMG‐CoA reductase inhibitor with lipid‐lowering properties. This study aims to investigate the role of RVS in plaque formation in atherosclerosis (AS) and its functional mechanism. ApoE−/− mice were fed a high‐fat diet to generate a mouse model of AS.
Xin Fu, Chuang Liu, Ya‐Li Chen, Jie‐Lin Qin, Ting‐Ting Wang, Shan‐Shan Fu   +5 more
wiley   +1 more source

Data from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis

, 2023
Satoshi Inoue, Nick Harper, Renata Walewska, Martin J.S. Dyer, Gerald M. Cohen   +4 more
openalex   +1 more source

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source